Journal of diabetes research · 2025
Therapeutic Potential of Acalypha wilkesiana in Type 2 Diabetes: A Review.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Inshutiyimana Samuel, Yesh Patel Dineshbhai, Aleu Michael Matiop, Sebata Aibekhanya Nkosana, Ajumesi Kenfa, Norhayati
Аннотация
BACKGROUND: Type 2 diabetes mellitus (T2DM) refers to a chronic metabolic disorder that results from insulin resistance, leading to impaired insulin action and uncontrolled plasma glucose levels. Acalypha wilkesiana is among medicinal plants that are ethnobotanically used in the management of T2DM. However, there is a paucity of information on its antidiabetic potential. This review is aimed at providing a current understanding of the mechanism of action, potency, and safety of Acalypha wilkesiana in T2DM therapy.
METHODS: A narrative review was thoroughly conducted by searching Google Scholar and PubMed databases using a predefined combination of keywords. All gathered articles were reviewed for the content regarding T2DM, Acalypha wilkesiana, mechanism of action, and safety. A total of 44 articles were considered in this review.
RESULTS: Several experimental studies revealed that extracts of Acalypha wilkesiana inhibit α-glucosidase and α-amylase, which normally break down carbohydrates postprandially. Notably, the ethanolic root bark extracts of Acalypha wilkesiana have shown lower inhibitory concentrations compared to those of both the plant extracts in other solvents and the acarbose drug, emphasizing its greater potency. Additionally, the leaves of Acalypha wilkesiana have been reported to have no harmful effects on the red blood cells of diabetic rabbits and can even restore the alloxan-induced impairment of pancreas and spleen cells.
CONCLUSION: Acalypha wilkesiana demonstrates antihyperglycemic activity and can reverse the dysfunction of critical organs. It promises advances in the development of antihyperglycemic agents which are more efficacious and safer than synthetic agents. However, clinical trials should be conducted to establish human-tailored doses, ensuring an improved safety profile of the plant in the treatment of T2DM.
METHODS: A narrative review was thoroughly conducted by searching Google Scholar and PubMed databases using a predefined combination of keywords. All gathered articles were reviewed for the content regarding T2DM, Acalypha wilkesiana, mechanism of action, and safety. A total of 44 articles were considered in this review.
RESULTS: Several experimental studies revealed that extracts of Acalypha wilkesiana inhibit α-glucosidase and α-amylase, which normally break down carbohydrates postprandially. Notably, the ethanolic root bark extracts of Acalypha wilkesiana have shown lower inhibitory concentrations compared to those of both the plant extracts in other solvents and the acarbose drug, emphasizing its greater potency. Additionally, the leaves of Acalypha wilkesiana have been reported to have no harmful effects on the red blood cells of diabetic rabbits and can even restore the alloxan-induced impairment of pancreas and spleen cells.
CONCLUSION: Acalypha wilkesiana demonstrates antihyperglycemic activity and can reverse the dysfunction of critical organs. It promises advances in the development of antihyperglycemic agents which are more efficacious and safer than synthetic agents. However, clinical trials should be conducted to establish human-tailored doses, ensuring an improved safety profile of the plant in the treatment of T2DM.